5acm: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
 ==Mcg immunoglobulin variable domain with methylene blue==
-<StructureSection load='5acm' size='340' side='right' caption='[[5acm]], [[Resolution|resolution]] 1.05&Aring;' scene=''>
+<StructureSection load='5acm' size='340' side='right'caption='[[5acm]], [[Resolution|resolution]] 1.05&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[5acm]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5ACM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ACM FirstGlance]. <br>
+<table><tr><td colspan='2'>[[5acm]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5ACM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5ACM FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MBT:3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM'>MBT</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.05&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5acl|5acl]]</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MBT:3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM'>MBT</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5acm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5acm OCA], [http://pdbe.org/5acm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5acm RCSB], [http://www.ebi.ac.uk/pdbsum/5acm PDBsum]</span></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5acm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5acm OCA], [https://pdbe.org/5acm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5acm RCSB], [https://www.ebi.ac.uk/pdbsum/5acm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5acm ProSAT]</span></td></tr>
 </table>
+== Function ==
+[https://www.uniprot.org/uniprot/LV208_HUMAN LV208_HUMAN] V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> <ref>PMID:24600447</ref>
 <div style="background-color:#fffaf0;">
 == Publication Abstract from PubMed ==
@@ Line 20: / Line 23: @@
 __TOC__
 </StructureSection>
-[[Category: Brumshtein, B]]
+[[Category: Homo sapiens]]
-[[Category: Cascio, D]]
+[[Category: Large Structures]]
-[[Category: Eisenberg, D S]]
+[[Category: Brumshtein B]]
-[[Category: Esswein, S R]]
+[[Category: Cascio D]]
-[[Category: Ly, A T]]
+[[Category: Eisenberg DS]]
-[[Category: Phillips, M L]]
+[[Category: Esswein SR]]
-[[Category: Salwinski, L]]
+[[Category: Ly AT]]
-[[Category: Sawaya, M R]]
+[[Category: Phillips ML]]
-[[Category: Immune system]]
+[[Category: Salwinski L]]
-[[Category: Immunoglobulin variable domain]]
+[[Category: Sawaya MR]]
-[[Category: Mcg]]
-[[Category: Methylene blue]]